Follow the people · Insider
Andrew Booth
Andrew Booth files insider transactions with the SEC as a chief financial officer of AbCellera Biologics (ABCL). We hold 2 disclosed purchases and sales filed since 9 June 2021, 1 of them in the last 90 days.
- Files forABCL
- Disclosed buys and sells2 in all, 1 in the last 90 days
- Last disclosure14 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 7 June 2021 — 14 August 2026Chief Financial Officer · AbCellera Biologics (ABCL)26 Form 4 lines · source: SEC Form 4
Everything they disclosed
26 entries, newest first — one per disclosure report, one per Form 4 line- ▲ bought on the open market 37,200 shares of AbCellera BiologicsSEC Form 414 August 2026Common Shares · traded 14 August 2026 · filed 14 August 2026
- exercised options over 250,000 shares of AbCellera BiologicsSEC Form 43 June 2026Common Shares · traded 3 June 2026 · filed 3 June 2026
- exercised options over 250,000 shares of AbCellera Biologics (a derivative holding)SEC Form 43 June 2026Share option (right to buy) · traded 3 June 2026 · filed 3 June 2026
- ▲ bought on the open market 42,600 shares of AbCellera BiologicsSEC Form 427 February 2026Common Shares · traded 27 February 2026 · filed 27 February 2026
- ▲ bought on the open market 42,600 shares of AbCellera BiologicsSEC Form 427 February 2026Common Shares · traded 27 February 2026 · filed 27 February 2026
- was granted 808,898 shares of AbCellera Biologics (a derivative holding)SEC Form 45 January 2026Share option (right to buy) · traded 1 January 2026 · filed 5 January 2026
- was granted 808,898 shares of AbCellera Biologics (a derivative holding)SEC Form 45 January 2026Share option (right to buy) · traded 1 January 2026 · filed 5 January 2026
- was granted 1,352,054 shares of AbCellera Biologics (a derivative holding)SEC Form 43 January 2025Share option (right to buy) · traded 1 January 2025 · filed 3 January 2025
- was granted 770,416 shares of AbCellera Biologics (a derivative holding)SEC Form 416 January 2024Share option (right to buy) · traded 14 January 2024 · filed 16 January 2024
- ▲ bought on the open market 14,500 shares of AbCellera BiologicsSEC Form 426 May 2023Common Shares · traded 26 May 2023 · filed 26 May 2023
- exercised options over 50,000 shares of AbCellera Biologics (a derivative holding)SEC Form 422 December 2022Share option (right to buy) · traded 20 December 2022 · filed 22 December 2022
- exercised options over 50,000 shares of AbCellera BiologicsSEC Form 422 December 2022Common Shares · traded 20 December 2022 · filed 22 December 2022
- gave away 50,000 shares of AbCellera BiologicsSEC Form 422 December 2022Common shares · traded 20 December 2022 · filed 22 December 2022
- was granted 485,661 shares of AbCellera Biologics (a derivative holding)SEC Form 45 December 2022Share Options (right to buy) · traded 1 December 2022 · filed 5 December 2022
- ▲ bought on the open market 85,000 shares of AbCellera BiologicsSEC Form 416 May 2022Common Shares · traded 12 May 2022 · filed 16 May 2022
- gave away 500,000 shares of AbCellera BiologicsSEC Form 43 February 2022Common Shares · traded 10 December 2021 · filed 3 February 2022
- exercised options over 500,000 shares of AbCellera Biologics (a derivative holding)SEC Form 410 December 2021Share Options (right to buy) · traded 10 December 2021 · filed 10 December 2021
- exercised options over 500,000 shares of AbCellera BiologicsSEC Form 410 December 2021Common Shares · traded 10 December 2021 · filed 10 December 2021
- was granted 406,020 shares of AbCellera Biologics (a derivative holding)SEC Form 49 December 2021Share Option (right to buy) · traded 7 December 2021 · filed 9 December 2021
- ▲ bought on the open market 53,500 shares of AbCellera BiologicsSEC Form 415 November 2021Common Shares · traded 11 November 2021 · filed 15 November 2021
- ▲ bought on the open market 14,000 shares of AbCellera BiologicsSEC Form 415 November 2021Common Shares · traded 11 November 2021 · filed 15 November 2021
- ▼ sold on the open market 1,200,000 shares of AbCellera BiologicsSEC Form 410 June 2021Common Shares · traded 9 June 2021 · filed 10 June 2021
- exercised options over 600,000 shares of AbCellera BiologicsSEC Form 49 June 2021Common Shares · traded 7 June 2021 · filed 9 June 2021
- exercised options over 600,000 shares of AbCellera BiologicsSEC Form 49 June 2021Common Shares · traded 7 June 2021 · filed 9 June 2021
- exercised options over 600,000 shares of AbCellera Biologics (a derivative holding)SEC Form 49 June 2021Share Option (right to buy) · traded 7 June 2021 · filed 9 June 2021
- exercised options over 600,000 shares of AbCellera Biologics (a derivative holding)SEC Form 49 June 2021Share Option (right to buy) · traded 7 June 2021 · filed 9 June 2021
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.